This is an application for renewal of the Bay Area Breast Cancer Translational Research Program, a collaborative effort between the University of California, San Francisco (UCSF), and the California Pacific Medical Center (CPMC). The main themes of this SPORE are: * Developing therapies targeted at surface proteins uniquely expressed or overexpressed on breast cancer cells. * Identifying genetic abnormalities associated with progression of breast cancer from a precancerous condition to a state of unregulated growth, from in situ expansion to invasive and metastatic behavior, and from a drug sensitive to a drug resistant phenotype. * Developing therapies designed to inhibit enzymes of critical importance in the early stages of breast cancer cell invasion. * Constructing gene therapies that target membrane proteins and carry genes into the cancer cell that will either make it more sensitive to toxins or make a target of the host immune response. * Evaluating the extent to which possible targets of therapy are associated with the prognosis or response to therapy of patients with breast cancer. * Identifying women at high risk of developing breast cancer and discovering new approaches to preventing cancer in these high risk women. The research program will draw on outstanding molecular biology programs of UCSF, the breast cancer research program on prognostic factors currently funded by a PO-1 at CPMC, the newly developed multidisciplinary breast clinic at the UCSF cancer center, and the extensive clinical programs associated with the Breast Health Center at CPMC. The applications consists of four principal research projects, two developing projects, approximately 5 pilot projects per year, seven cores, and support for the career development of two new faculty members committed to breast cancer research. The principal research projects are: #1 """"""""The development of membrane receptor targeted and tumoricidal breast cancer therapy."""""""" #2 """"""""DNA sequence copy number abnormalities in human breast cancer."""""""" #3 """"""""Molecular markers defining groups of women at unusually high risk of developing cancer."""""""" #4 """"""""Therapeutic blockade of urokinase in breast cancer."""""""" """"""""The proposal includes two new developing projects: """"""""Ligand mediated targeting of retrovirus to breast cancer,"""""""" and """"""""Genomic instability in carcinogenesis of the breast."""""""" Two new cores are described: an immunohistopathology core and an advocacy core. Cores previously part of this SPORE include: #1 Administration; #2 Human fresh tissue bank; #3 An animal facility ; #4 Epidemiology and biostatistics; #6 Clinical core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058207-08S1
Application #
6348768
Study Section
Special Emphasis Panel (SRC (27))
Program Officer
Kuzmin, Igor A
Project Start
1992-09-30
Project End
2002-11-30
Budget Start
1999-08-01
Budget End
2002-11-30
Support Year
8
Fiscal Year
2000
Total Cost
$2,572,530
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41
Molinaro, Annette M; Sison, Jennette D; Ljung, Britt-Marie et al. (2016) Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. Breast Cancer Res Treat 157:351-361
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45

Showing the most recent 10 out of 339 publications